Methicillin-resistant Staphylococcus aureus (MRSA): Nursing process (ADPIE)

Last updated: January 26, 2022

Methicillin-resistant Staphylococcus aureus (MRSA): Nursing process (ADPIE)

Synthesis Of Nursing Practice

Synthesis Of Nursing Practice

Left-sided heart failure: Nursing process (ADPIE)
Heart failure
Heart failure: Pathology review
Heart failure: Clinical
Normal heart sounds
Abnormal heart sounds
Anatomy of the heart
Congenital heart defects: Clinical
Cardiac conduction system
Post-COVID syndrome: Heart, lungs and clotting
Heart blocks: Pathology review
Aortic aneurysm: Nursing process (ADPIE)
Coronary artery disease (CAD) and angina pectoris: Nursing process (ADPIE)
Hypertension: Nursing process (ADPIE)
Myocardial infarction (MI): Nursing process (ADPIE)
Pericardial effusion and cardiac tamponade: Nursing process (ADPIE)
Rheumatic heart disease: Nursing process (ADPIE)
Antihyperlipidemics - Statins: Nursing pharmacology
Calcium-channel blockers: Nursing pharmacology
Angiotensin II receptor blockers (ARBs): Nursing pharmacology
Angiotensin-converting enzyme (ACE) inhibitors: Nursing pharmacology
Antiarrhythmics: Nursing pharmacology
Antihyperlipidemics - Miscellaneous: Nursing pharmacology
Antihyperlipidemics - Fibrates: Nursing pharmacology
Diabetes insipidus: Nursing process (ADPIE)
Diabetes mellitus (DM): Nursing process (ADPIE)
Diabetic ketoacidosis (DKA): Nursing process (ADPIE)
Hyperosmolar hyperglycemic state (HHS): Nursing process (ADPIE)
Hyperthyroidism: Nursing process (ADPIE)
Hypothyroidism: Nursing process (ADPIE)
Syndrome of inappropriate antidiuretic hormone (SIADH): Nursing process (ADPIE)
Medications affecting the parathyroid glands: Nursing pharmacology
Medications for antidiuretic hormone (ADH) disorders: Nursing pharmacology
Medications for thyroid disorders: Nursing pharmacology
Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics: Nursing pharmacology
Oral antidiabetic medications - Alpha-glucosidase inhibitors: Nursing pharmacology
Oral antidiabetic medications - Biguanides and thiazolidinediones: Nursing pharmacology
Oral antidiabetic medications - DPP-4 inhibitors: Nursing pharmacology
Oral antidiabetic medications - Sulfonylureas and meglitinides: Nursing pharmacology
Oral antidiabetic medications - Sodium-glucose co-transporter-2 (SGLT-2) inhibitors: Nursing pharmacology
Insulin: Nursing pharmacology
Medications for growth hormone disorders: Nursing pharmacology
Glucocorticoids and mineralocorticoids: Nursing pharmacology
Epistaxis: Nursing process (ADPIE)
Eye injury: Nursing process (ADPIE)
Glaucoma: Nursing process (ADPIE)
Tonsillitis: Nursing process (ADPIE)
Antiglaucoma medications: Nursing pharmacology
Eye anesthetics: Nursing pharmacology
Mydriatics and cycloplegics: Nursing pharmacology
Ophthalmic anti-inflammatories and anti-infectives: Nursing pharmacology
Appendicitis: Nursing process (ADPIE)
Celiac disease: Nursing process (ADPIE)
Cirrhosis: Nursing process (ADPIE)
Gastroesophageal reflux disease (GERD): Nursing process (ADPIE)
Hiatal hernia: Nursing process (ADPIE)
Pancreatitis: Nursing process (ADPIE)
Peptic ulcer disease (PUD): Nursing process (ADPIE)
Antacids: Nursing pharmacology
Antidiarrheals: Nursing pharmacology
Laxatives: Nursing pharmacology
Weight loss medications: Nursing pharmacology
Antiemetics: Nursing pharmacology
Gallstone-dissolving agents: Nursing pharmacology
Gastric mucosal protective agents: Nursing pharmacology
Antispasmodics (GI): Nursing pharmacology
Histamine H2 antagonists: Nursing pharmacology
Proton pump inhibitors (PPIs): Nursing pharmacology
Treatment for Helicobacter pylori: Nursing pharmacology
Medications for hepatic encephalopathy: Nursing pharmacology
Diuretics - Osmotic and carbonic anhydrase inhibitors: Nursing pharmacology
Diuretics - Thiazide, thiazide-like, loop, and potassium-sparing diuretics: Nursing pharmacology
Antispasmodics (GU): Nursing pharmacology
Cholinergic therapy (GU): Nursing pharmacology
Acute kidney injury (AKI): Nursing process (ADPIE)
Benign prostatic hyperplasia (BPH): Nursing process (ADPIE)
Urinary incontinence - Stress: Nursing process (ADPIE)
Urinary tract infections (UTIs): Nursing process (ADPIE)
Hemophilia: Nursing process (ADPIE)
Leukemia: Nursing process (ADPIE)
Sickle cell disease: Nursing process (ADPIE)
Anticoagulants - Heparin: Nursing pharmacology
Anticoagulants - Warfarin: Nursing pharmacology
Antiplatelet agents: Nursing pharmacology
Hemostatics: Nursing pharmacology
Iron preparations: Nursing pharmacology
Thrombolytics: Nursing pharmacology
Blood products: Nursing pharmacology
Antihyperlipidemics - Bile acid sequestrants and cholesterol absorption inhibitors: Nursing pharmacology
Anticoagulants - Direct thrombin and factor Xa inhibitors: Nursing pharmacology
Hematopoietic growth factors: Nursing pharmacology
Anaphylaxis: Nursing process (ADPIE)
Lyme disease: Nursing process (ADPIE)
Non-biologic disease-modifying antirheumatic drug (DMARD) therapy: Nursing pharmacology
Vaccines: Nursing pharmacology
Immunoglobulins: Nursing pharmacology
Immunosuppressants for autoimmune diseases: Nursing pharmacology
Immunomodulators: Nursing pharmacology
Disease-modifying therapy for multiple sclerosis: Nursing pharmacology
Atopic dermatitis: Nursing process (ADPIE)
Frostbite: Nursing process (ADPIE)
Methicillin-resistant Staphylococcus aureus (MRSA): Nursing process (ADPIE)
Pressure injury: Nursing process (ADPIE)
Debridement agents: Nursing pharmacology
Keratolytics: Nursing pharmacology
Antibiotics - Topical: Nursing pharmacology
Antifungals - Topical: Nursing pharmacology
Corticosteroids - Topical: Nursing pharmacology
Medications for acne vulgaris: Nursing pharmacology
Acute compartment syndrome: Nursing process (ADPIE)
Fractures: Nursing process (ADPIE)
Gout: Nursing process (ADPIE)
Musculoskeletal injuries: Nursing process (ADPIE)
Rheumatoid arthritis (RA): Nursing process (ADPIE)
Acetylcholinesterase inhibitors for myasthenia gravis: Nursing pharmacology
Analgesics: Nursing pharmacology
Antiepileptics: Nursing pharmacology
Medications for Alzheimer disease: Nursing pharmacology
Skeletal muscle relaxants: Nursing pharmacology
Medications for migraines: Nursing pharmacology
Meningitis: Nursing process (ADPIE)
Parkinson disease: Nursing process (ADPIE)
Seizure disorder: Nursing process (ADPIE)
Stroke: Nursing process (ADPIE)
Trigeminal neuralgia: Nursing process (ADPIE)
Breast cancer: Nursing process (ADPIE)
Tumor lysis syndrome (TLS): Nursing Process (ADPIE)
Plant extracts for chemotherapy: Nursing pharmacology
Antitumor antibiotics: Nursing pharmacology
Alkylating agents: Nursing pharmacology
Hormones and hormone modulators for cancer: Nursing pharmacology
Other antineoplastics: Nursing pharmacology
Antimetabolites: Nursing pharmacology
Platinum-based agents: Nursing pharmacology
Peripheral arterial disease (PAD): Nursing process (ADPIE)
Peripheral venous disease (PVD): Nursing process (ADPIE)
Candidiasis: Nursing process (ADPIE)
Gonorrhea and chlamydia: Nursing process (ADPIE)
Pelvic inflammatory disease (PID): Nursing process (ADPIE)
Asthma: Nursing process (ADPIE)
Bacterial pneumonia: Nursing process (ADPIE)
Carbon monoxide poisoning: Nursing process (ADPIE)
Chronic obstructive pulmonary disease (COPD): Nursing process (ADPIE)
Epiglottitis: Nursing process (ADPIE)
Foreign body aspiration and upper airway obstruction: Nursing process (ADPIE)
Laryngotracheobronchitis (LTB) and croup: Nursing process (ADPIE)
Smoke inhalation injury: Nursing process (ADPIE)
Venous thromboembolism (VTE): Nursing process (ADPIE)
Antihistamines: Nursing pharmacology
Bronchodilators: Nursing pharmacology
Corticosteroids - Inhaled: Nursing pharmacology
Mast cell stabilizers - Inhaled: Nursing pharmacology
Leukotriene modifiers: Nursing pharmacology
Medications to control airway secretions: Nursing pharmacology
Oxygen therapy: Nursing pharmacology
Respiratory stimulants: Nursing pharmacology
Applying sterile gloves
Cardioversion
Maintaining an airway
Removing an intravenous line
Venipuncture for blood sampling
Clinical Skills: Abdominal Assessment
Clinical skills: Medication administration - Giving transcutaneous medication
Clinical skills: Patient controlled analgesia
COVID-19: Nursing

Notes

METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)

KEY POINTS
NOTES
PATIENT REPORT
  • 17-year-old boy
  • Red, painful sore on upper left thigh
  • Filled with pus
  • Diagnosis: community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA)

PATHOPHYSIOLOGY
  • MRSA
    • Strain of Staphylococcus aureus 
    • Resistance to lactam antibiotics
    • CA-MRSA
    • Healthcare-associated MRSA (HA-MRSA)
  • Risk factors
    • Chronic illness
    • Skin damage
    • Living in crowded or unsanitary conditions
    • Immunosuppression
  • Signs and symptoms
    • Localized skin and soft tissue infection
    • Red bumps resemble pimples or spider bites
    • Increased warmth, erythema, edema, tenderness
    • Fluid-filled cavity or purulent drainage
    • Fever
    • Lethargy
  • Complications
    • Sepsis
    • Endocarditis
    • Osteomyelitis
    • Necrotizing pneumonia
    • Septic joint

DIAGNOSIS AND TREATMENT
  • Diagnosis
    • Culture
    • DNA polymerase chain reaction
  • Treatment
    • Antibiotics

ASSESSMENT
  • Painful leg
  • Worried about wrestling practice
  • Temperature: 98.6 F (37 C)
  • Heart rate: 62
  • Respiratory rate: 14
  • Clear lung sounds
  • Blood pressure: 118/70 mmHg
  • Pain: 7/10
  • Circular area of erythema and edema with raised pustule
  • Surrounding skin warm and tender

NURSING DIAGNOSES
  • Impaired skin integrity related to pustule formation
  • Pain related to injury and inflammation
  • Risk of infection related to increased environmental exposure to MRSA
  • Anxiety related to sports activities

PLANNING
  • Reduce erythema, edema, warmth, and pain
  • Decrease anxiety
  • Prevent spread of infection

IMPLEMENTATION
  • Assist with incision and drainage
  • Collect culture
  • Administer medications as prescribed
  • Teach about medications
  • Stress importance of hand washing, hydration, and high protein diet
  • Stress importance of prevention of spread

EVALUATION
  • No new infections
  • Circular area of erythema with pustule decreasing in size
  • Scant amount exudate
  • Pain: 4/10
  • No spread of infection

Transcript

Watch video only

Elias Moore, a 17-year-old African American male, who is on his school’s wrestling team who developed a red, painful sore on the upper left side of his thigh.

At first it looked like a spider bite, but the next day it began to swell and formed a bump filled with pus.

He showed it to his mother who took him to the pediatrician’s office where he was diagnosed with community-acquired methicillin-resistant Staphylococcus aureus, also known as CA-MRSA.

MRSA is a strain of Staphylococcus aureus, or staph for short.

It’s often referred to as a superbug due to its resistance to the widely-used beta lactam antibiotics such as penicillins, cephalosporins, and carbapenems.

This is because MRSA has the mecA gene that allows the bacteria to produce proteins that are more difficult for the medications to bind to, and it also codes for the beta lactamase enzyme which can break these medications down.

Unfortunately, due to the misuse and overuse of antibiotic treatment by both clinicians and patients, MRSA has become more common in recent years.

The two types are healthcare-associated MRSA, or HA-MRSA, and community-associated MRSA, or CA-MRSA.

HA-MRSA infections are a leading cause of infection in hospitals due in part to the fact that it creates biofilms that colonize medical devices like catheters, endotracheal tubing, and surgical instruments.

On the other hand, CA-MRSA occurs when there’s been no exposure to the healthcare setting and it can affect healthy individuals.

CA-MRSA is primarily transmitted from direct or indirect contact and can either asymptomatically colonize or cause an active infection.

Risk factors for developing an active infection include chronic illnesses like kidney disease, diabetes, or malignancies; activities that could cause damage to the skin, like contact sports and intravenous drug use; living in crowded or unsanitary conditions like army barracks or prisons; and those with HIV or using immune suppressing medications like corticosteroids.

The infection occurs when immunosuppression or altered skin integrity allows the bacteria to bypass the body’s natural defenses and enter the tissue.

CA-MRSA typically presents as a localized skin and soft tissue infection, or SSTI.

Single or multiple red bumps that resemble pimples or spider bites initially appear in areas of compromised skin integrity or in areas often covered with hair like the armpits, groin, or back of the neck.

Increased warmth, erythema, edema, tenderness, a palpable fluid-filled cavity, or purulent drainage may occur within the infected site.

Fever and lethargy are also commonly experienced at this time.

If left untreated or poorly managed, these localized infections can quickly become systemic and result in sepsis, endocarditis, osteomyelitis, necrotizing pneumonia, and septic joints.

CA-MRSA can be diagnosed through a variety of tests.

Cultures from suspected sources of infection, such as wound scraping, sputum, blood, or urine, can be collected for testing.

If the culture’s results remain inconclusive, the DNA polymerase chain reaction, or PCR, of MRSA is highly sensitive and currently considered the gold standard for determining infectious type.

To test for MRSA colonization and not active infection, DNA PCR of MRSA from a nares swab is often utilized.

Treatment for MRSA involves quick initiation of antibiotic therapy.

HA-MRSA infections typically have more resistance to medications when compared to CA-MRSA.

In fact it often resists non-beta lactam antibiotics, making it more difficult to treat.

Common oral antibiotics prescribed include trimethoprim/sulfamethoxazole, doxycycline or minocycline, clindamycin, linezolid or tedizolid, and delafloxacin.

Intravenous antibiotics may be initiated if the oral medications prove ineffective, if systemic infection occurs, or if the SSTI occurred near an implanted device.

In such cases, IV vancomycin is often the preferred drug among clinicians.

However, new strains of vancomycin-resistant Staphylococcus aureus, known as VRSA, have become more common in recent years.